Disclaimer: This article is an educational review of scientific literature and does not account for individual health conditions. Always consult with healthcare professionals before making any health-related decisions.

When vaccines for Respiratory Syncytial Virus (RSV) finally came out for older adults, it honestly felt like a huge win for public health. RSV is no minor cold for those aged 60 and above; it's a serious threat, particularly to the cardiorespiratory system. With strong data indicating their effectiveness and a well-established safety profile, plus clear guidance from expert bodies, research suggests widespread consideration of vaccination. Yet, a look at the real-world numbers tells a surprising story, forcing us to ask: what’s happening between the science and the arm?

For years, really protecting older adults from severe RSV was just tough. Now, though, we actually have specific RSV vaccines available, and the research provides substantial evidence of their potential benefits. Studies indicate substantial potential for protection against the virus's worst outcomes. For instance, pooled estimates from real-world data indicated these vaccines were 74.8% effective at preventing RSV-related hospital admissions and 79.8% effective against severe RSV-associated disease in adults aged 60 years and older ^[3]. Looking at individual vaccines, research indicated one specific RSV vaccine reduced RSV-related hospitalizations in older adults by 60-65%, while studies found another demonstrated 58-63% efficacy in that same age group. Interestingly, research indicated this latter vaccine also demonstrated 68-72% efficacy in reducing infant RSV hospitalization if the mothers were immunized ^[2].

Beyond just preventing RSV respiratory illness directly, the evidence also hints at some broader protective effects. A pragmatic clinical trial involving over 130,000 adults aged 60 years or older in Denmark investigated the impact of a bivalent RSV prefusion F protein-based vaccine. This research found a statistically significant 9.9% vaccine effectiveness against all-cause cardiorespiratory hospitalization ^[1]. While a 9.9% reduction might sound modest, considering "all-cause" hospitalizations related to both the heart and lungs, it points to a potential downstream benefit for overall cardiorespiratory health in older populations ^[1]. Research indicates that all evaluated RSV vaccines also demonstrated their ability to generate a robust immune response, inducing a 5-7-fold increase in neutralizing antibody titers that were sustained for up to 12 months ^[2].

With such indicated benefits, of course, the safety profile becomes equally important for a comprehensive understanding. The systematic reviews and meta-analyses consistently indicate these RSV vaccines generally have a well-established safety profile. Common reactions are typically mild and localized: injection-site pain occurred in about 23-29% of recipients, and systemic symptoms, such as fatigue or headache, were reported in 7-11% ^[2], ^[4]. Serious adverse events were rare, affecting less than 1% of participants in studies ^[2]. Of note, Guillain-Barré syndrome (GBS), a rare neurological disorder, has been reported following vaccination, with rates estimated between 5.2 and 18.2 cases per million doses ^[3]. This information, while important for transparency, contextualizes the overall safety profile, which research indicates is generally favorable, against the background of large-scale vaccine use.

Recognizing all this evidence, expert bodies have stepped up and issued clear guidance. For example, specific recommendations from expert bodies suggest RSV vaccination for all adults aged 75 years and older, and for high-risk adults aged 50-74 years ^[5]. This level of endorsement typically signals that the medical community sees significant value in widespread vaccination for eligible groups.

Here’s where the story takes a turn. Despite the substantial evidence of effectiveness, the generally well-established safety profile, and the expert recommendations, the real-world uptake of RSV vaccine among US adults aged 60 years and older was strikingly low, only 18.0% during the 2023/24 RSV season ^[3]. This figure is a sharp contrast to the potential public health benefits. Why isn't this robust scientific consensus translating into higher rates of vaccination uptake and potential risk reduction for a vulnerable population? The research highlights this significant gap between what research indicates is effective and what is actually happening in communities.

This low uptake isn't just a number; it represents missed opportunities to prevent severe illness, hospitalizations, and potentially even broader cardiorespiratory events in older adults who stand to gain the most from this protection. The available data presents a compelling case for vaccination, yet the challenge clearly extends beyond scientific proof alone.

💊 Bottom Line The science behind RSV vaccines for older adults is compelling: they offer strong protection against severe disease, reduce hospitalizations, and even show promise in mitigating broader cardiorespiratory risks ^[1], ^[2], ^[3]. With a generally favorable safety profile ^[2], ^[4] and clear expert recommendations ^[5], the foundation for widespread adoption seems solid. However, the strikingly low real-world uptake of 18% reveals a profound disconnect between established public health value and actual implementation ^[3]. This gap signals a complex challenge that robust scientific evidence alone has not yet overcome.

---

References

[1] Lassen M, Johansen N, Christensen S, et al. Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial. JAMA. 2025. PMID: 40884493
https://pubmed.ncbi.nlm.nih.gov/40884493/

[2] Alandijany T, Qashqari F. Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia. Frontiers in immunology. 2025. PMID: 40901480
https://pubmed.ncbi.nlm.nih.gov/40901480/

[3] Trusinska D, Lee B, Ferdous S, et al. Real-world evidence on RSV vaccine uptake, effectiveness, and safety in older adults: a systematic review and meta-analysis. The Lancet regional health. Europe. 2026. PMID: 41767892
https://pubmed.ncbi.nlm.nih.gov/41767892/

[4] Xiao Q, Yang R, Zhang L, et al. Safety and Efficacy of Respiratory Syncytial Virus Vaccination in Older Adults: Systematic Review and Meta-Analysis of Randomized Controlled Trials. JMIR public health and surveillance. 2025. PMID: 41344873
https://pubmed.ncbi.nlm.nih.gov/41344873/

[5] Choi J, Rhee C, Hwang Y, et al. Expert Consensus Statement on the Disease Burden and Vaccination for Respiratory Syncytial Virus Infection in Adults. Tuberculosis and respiratory diseases. 2026. PMID: 41255075
https://pubmed.ncbi.nlm.nih.gov/41255075/